| ID | 1138 |
| Name of the vaccine | BIOTHRAX |
| Microbe | Bacteria |
| Disease name | Anthrax |
| Name of bacteria | Bacillus anthracis |
| Type of vaccine | Inactivated |
| Nucleic acid content | Linear DNA |
| Age | 18 to 65 years |
| Description of the vaccine | Anthrax vaccine adsorbed (AVA). |
| Name of the manufacturer | Emergent BioDefense Operations |
| Name of the manufacturing country | United States |
| Year of manufacture | 1970 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive, rod-shaped bacteria. |
| Efficacy | 92.5% for all types of anthrax disease. |
| Vaccine formulation | Suspension for injection |
| Dosage | Dose - 0.5 ml.
Pre-Exposure Prophylaxis -
Primary Series : 0,1 and 6 months
Booster Series : 6 and 12 months and at 12-month intervals.
Post-Exposure Prophylaxis -
Primary series : 0, 2 and 4 weeks. |
| Mechanism of action | Neutralizes the activities of the cytotoxic lethal toxin and edema toxin of bacteria. |
| Route of administration | Intramuscular |
| Indications | Prevention of disease caused by Bacillus anthracis. Approved for pre-exposure prophylaxis and post-exposure prophylaxis. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Tenderness, pain, erythema, edema and arm motion limitation. |
| Post vaccination | Yes (Zoonotic Disease) |
| Dose type | Combination doses |
| Interspecies transfer | Yes (Zoonotic disease through contact with an infected animal or by inhaling spores) |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/71954/download |
| Other name | NA |
| Additional Links | NA
|